Indicator type;Size of the company;Total
Number of companies carrying out R&D in Biotechnology;Less than 250 employees;1,284
Number of companies carrying out R&D in Biotechnology;250 and more employees;160
Number of companies carrying out R&D in Biotechnology;Total;1,444
% Companies by type of biotechnology used: Genetic Code;Less than 250 employees;29.7
% Companies by type of biotechnology used: Genetic Code;250 and more employees;38.6
% Companies by type of biotechnology used: Genetic Code;Total;30.7
% Companies by type of biotechnology used: Functional Units;Less than 250 employees;36.6
% Companies by type of biotechnology used: Functional Units;250 and more employees;45.5
% Companies by type of biotechnology used: Functional Units;Total;37.6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Less than 250 employees;20.0
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;250 and more employees;31.6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;21.3
% Companies by type of biotechnology used: Bioprocesses;Less than 250 employees;49.5
% Companies by type of biotechnology used: Bioprocesses;250 and more employees;62.6
% Companies by type of biotechnology used: Bioprocesses;Total;50.9
% Companies by type of biotechnology used: Subcellular Organisms;Less than 250 employees;6.8
% Companies by type of biotechnology used: Subcellular Organisms;250 and more employees;18.3
% Companies by type of biotechnology used: Subcellular Organisms;Total;8.1
% Companies by type of biotechnology used: Bioinformatics;Less than 250 employees;22.1
% Companies by type of biotechnology used: Bioinformatics;250 and more employees;26.6
% Companies by type of biotechnology used: Bioinformatics;Total;22.6
% Companies by type of biotechnology used: Nanobiotechnology;Less than 250 employees;9.8
% Companies by type of biotechnology used: Nanobiotechnology;250 and more employees;10.2
% Companies by type of biotechnology used: Nanobiotechnology;Total;9.8
% Companies by type of biotechnology used: Other;Less than 250 employees;16.8
% Companies by type of biotechnology used: Other;250 and more employees;17.2
% Companies by type of biotechnology used: Other;Total;16.9
Companies in which biotechnology activities are: Main and/or exclusive;Less than 250 employees;604
Companies in which biotechnology activities are: Main and/or exclusive;250 and more employees;25
Companies in which biotechnology activities are: Main and/or exclusive;Total;629
Companies in which biotechnology activities are: A secondary business line;Less than 250 employees;215
Companies in which biotechnology activities are: A secondary business line;250 and more employees;47
Companies in which biotechnology activities are: A secondary business line;Total;262
Companies in which biotechnology activities are: A necessary tool for production;Less than 250 employees;465
Companies in which biotechnology activities are: A necessary tool for production;250 and more employees;88
Companies in which biotechnology activities are: A necessary tool for production;Total;553
% Companies by final application areas of biotechnology use: Human Health;Less than 250 employees;44.7
% Companies by final application areas of biotechnology use: Human Health;250 and more employees;41.1
% Companies by final application areas of biotechnology use: Human Health;Total;44.3
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Less than 250 employees;16.2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;250 and more employees;12.1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;15.8
% Companies by final application areas of biotechnology use: Food Products;Less than 250 employees;29.4
% Companies by final application areas of biotechnology use: Food Products;250 and more employees;41.1
% Companies by final application areas of biotechnology use: Food Products;Total;30.7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Less than 250 employees;25.6
% Companies by final application areas of biotechnology use: Agriculture and Forestry;250 and more employees;20.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;24.9
% Companies by final application areas of biotechnology use: Environment;Less than 250 employees;17.3
% Companies by final application areas of biotechnology use: Environment;250 and more employees;13.9
% Companies by final application areas of biotechnology use: Environment;Total;16.9
% Companies by final application areas of biotechnology use: Industry;Less than 250 employees;12.5
% Companies by final application areas of biotechnology use: Industry;250 and more employees;13.3
% Companies by final application areas of biotechnology use: Industry;Total;12.6
R&D personnel in Biotechnology (PP);Less than 250 employees;10,452
R&D personnel in Biotechnology (PP);250 and more employees;7,291
R&D personnel in Biotechnology (PP);Total;17,743
R&D personnel in Biotechnology (PP): Research personnel;Less than 250 employees;6,309
R&D personnel in Biotechnology (PP): Research personnel;250 and more employees;3,136
R&D personnel in Biotechnology (PP): Research personnel;Total;9,445
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Less than 250 employees;4,144
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;250 and more employees;4,154
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8,298
R&D personnel in Biotechnology (PP). Women;Less than 250 employees;5,369
R&D personnel in Biotechnology (PP). Women;250 and more employees;4,538
R&D personnel in Biotechnology (PP). Women;Total;9,907
R&D personnel in Biotechnology (PP). Women: Research personnel;Less than 250 employees;3,273
R&D personnel in Biotechnology (PP). Women: Research personnel;250 and more employees;1,832
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5,104
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Less than 250 employees;2,096
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;250 and more employees;2,707
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4,802
R&D personnel in Biotechnology (FTE);Less than 250 employees;7,232.7
R&D personnel in Biotechnology (FTE);250 and more employees;5,760.8
R&D personnel in Biotechnology (FTE);Total;12,993.4
R&D personnel in Biotechnology (FTE): Research personnel;Less than 250 employees;4,671.5
R&D personnel in Biotechnology (FTE): Research personnel;250 and more employees;2,398.3
R&D personnel in Biotechnology (FTE): Research personnel;Total;7,069.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Less than 250 employees;2,561.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;250 and more employees;3,362.4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5,923.6
R&D personnel in Biotechnology (FTE). Women;Less than 250 employees;3,763.9
R&D personnel in Biotechnology (FTE). Women;250 and more employees;3,707.8
R&D personnel in Biotechnology (FTE). Women;Total;7,471.8
R&D personnel in Biotechnology (FTE). Women: Research personnel;Less than 250 employees;2,449.2
R&D personnel in Biotechnology (FTE). Women: Research personnel;250 and more employees;1,421.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;3,870.1
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Less than 250 employees;1,314.8
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;250 and more employees;2,286.9
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,601.6
Expenditure on internal R&D in Biotechnology (thousands of euros);Less than 250 employees;691,268
Expenditure on internal R&D in Biotechnology (thousands of euros);250 and more employees;532,533
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1,223,801
1) By type of expenditure: Current expenditure;Less than 250 employees;614,656
1) By type of expenditure: Current expenditure;250 and more employees;493,534
1) By type of expenditure: Current expenditure;Total;1,108,189
1.1) Labour expenditure of research personnel;Less than 250 employees;221,957
1.1) Labour expenditure of research personnel;250 and more employees;138,965
1.1) Labour expenditure of research personnel;Total;360,922
1.2) Labour expenditure of technical and auxiliary personnel;Less than 250 employees;96,161
1.2) Labour expenditure of technical and auxiliary personnel;250 and more employees;124,379
1.2) Labour expenditure of technical and auxiliary personnel;Total;220,540
1.3) Other current expenditure;Less than 250 employees;296,538
1.3) Other current expenditure;250 and more employees;230,190
1.3) Other current expenditure;Total;526,727
2) By type of expenditure: Capital expenditure;Less than 250 employees;76,612
2) By type of expenditure: Capital expenditure;250 and more employees;39,000
2) By type of expenditure: Capital expenditure;Total;115,612
2.1) Land and buildings;Less than 250 employees;7,247
2.1) Land and buildings;250 and more employees;9,596
2.1) Land and buildings;Total;16,843
2.2) Equipment and tools;Less than 250 employees;37,708
2.2) Equipment and tools;250 and more employees;25,819
2.2) Equipment and tools;Total;63,527
2.3) Acquisition of specific R&D software;Less than 250 employees;2,767
2.3) Acquisition of specific R&D software;250 and more employees;1,191
2.3) Acquisition of specific R&D software;Total;3,959
2.4) Other R&D-specific IP products;Less than 250 employees;28,890
2.4) Other R&D-specific IP products;250 and more employees;2,394
2.4) Other R&D-specific IP products;Total;31,284
1.1) By origin of funds: Own funds;Less than 250 employees;471,465
1.1) By origin of funds: Own funds;250 and more employees;389,138
1.1) By origin of funds: Own funds;Total;860,603
1.2) By origin of funds: Funds from the Business sector;Less than 250 employees;77,630
1.2) By origin of funds: Funds from the Business sector;250 and more employees;50,371
1.2) By origin of funds: Funds from the Business sector;Total;128,002
1.3) By origin of funds: Funds from the Public Administration sector;Less than 250 employees;96,976
1.3) By origin of funds: Funds from the Public Administration sector;250 and more employees;22,523
1.3) By origin of funds: Funds from the Public Administration sector;Total;119,498
1.4) By origin of funds: Funds from the Higher Education sector;Less than 250 employees;647
1.4) By origin of funds: Funds from the Higher Education sector;250 and more employees;0
1.4) By origin of funds: Funds from the Higher Education sector;Total;647
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Less than 250 employees;1,563
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;250 and more employees;11,423
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12,986
1.6) By origin of funds: Funds from the rest of the world;Less than 250 employees;42,988
1.6) By origin of funds: Funds from the rest of the world;250 and more employees;59,078
1.6) By origin of funds: Funds from the rest of the world;Total;102,065
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Less than 250 employees;43,120
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);250 and more employees;80,276
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;123,396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Less than 250 employees;22,993
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;250 and more employees;65,992
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88,985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Less than 250 employees;20,127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;250 and more employees;14,284
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;34,412
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Less than 250 employees;41.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;250 and more employees;23.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;39.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Less than 250 employees;15.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;250 and more employees;16.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;15.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Less than 250 employees;22.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;250 and more employees;17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;22.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Less than 250 employees;11.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;250 and more employees;17.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;12.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Less than 250 employees;17.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;250 and more employees;15.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;17.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Less than 250 employees;18.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;250 and more employees;15.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;17.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Less than 250 employees;15.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;250 and more employees;20.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;16.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Less than 250 employees;41.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;250 and more employees;38.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;41.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Less than 250 employees;51.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;250 and more employees;44.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;50.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Less than 250 employees;20.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;250 and more employees;15.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;20.1
% Companies with international revenues related to biotechnology activities;Less than 250 employees;23.0
% Companies with international revenues related to biotechnology activities;250 and more employees;20.2
% Companies with international revenues related to biotechnology activities;Total;22.7
% Companies representing international revenues related to biotechnology activities;Less than 250 employees;8.2
% Companies representing international revenues related to biotechnology activities;250 and more employees;1.3
% Companies representing international revenues related to biotechnology activities;Total;2.1
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Less than 250 employees;55.4
% International revenues related to biotechnology activities distributed in: Revenues from the EU;250 and more employees;64.9
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;60.6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Less than 250 employees;44.6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;250 and more employees;35.1
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;39.4
% International revenues related to biotechnology activities by classification: International trade in goods and services;Less than 250 employees;93.9
% International revenues related to biotechnology activities by classification: International trade in goods and services;250 and more employees;82.8
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;87.8
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Less than 250 employees;3.8
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 and more employees;15.1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;10.1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Less than 250 employees;0.7
% International revenues related to biotechnology activities by classification: Subsidies from external sources;250 and more employees;2.0
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1.4
% International revenues related to biotechnology activities by classification: Other;Less than 250 employees;1.7
% International revenues related to biotechnology activities by classification: Other;250 and more employees;0.0
% International revenues related to biotechnology activities by classification: Other;Total;0.8